[GM-CSF: its use in onco-hematologic diseases].
Visani
G
G
Tosi
P
P
Benfenati
D
D
Colombini
R
R
Cenacchi
A R
AR
Gamberi
B
B
Lemoli
R M
RM
Tura
S
S
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000380:Agranulocytosis / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D003115:Colony-Stimulating Factors / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000009:adverse effects / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007938:Leukemia / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D014411:Neoplastic Stem Cells / Q000187:drug effects; D009503:Neutropenia / Q000188:drug therapy* / Q000209:etiology
D000970:Antineoplastic Agents; D003115:Colony-Stimulating Factors; D006133:Growth Substances; D016178:Granulocyte-Macrophage Colony-Stimulating Factor
Il GM-CSF: impiego nelle malattie oncoematologiche.